{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T23:44:14Z","timestamp":1780703054095,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["P50 HD060848"],"award-info":[{"award-number":["P50 HD060848"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.omtm.2025.101513","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:30:43Z","timestamp":1750059043000},"page":"101513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A systemically deliverable lipid-conjugated siRNA targeting DUX4 as an facioscapulohumeral muscular dystrophy therapeutic"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1088-3903","authenticated-orcid":false,"given":"Katelyn","family":"Daman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Biscans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimas","family":"Echeverria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisia","family":"Shmushkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Wolfson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia F.","family":"Alterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Khvorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles P.","family":"Emerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2025.101513_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mus.20522","article-title":"Facioscapulohumeral muscular dystrophy","volume":"34","author":"Tawil","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.omtm.2025.101513_bib2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtm.2025.101513_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-1119(99)00267-X","article-title":"Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element","volume":"236","author":"Gabriels","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.omtm.2025.101513_bib4","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/ejhg.2014.191","article-title":"Diagnostic approach for FSHD revisited: SMCHD1 mutations cause FSHD2 and act as modifiers of disease severity in FSHD1","volume":"23","author":"Larsen","year":"2015","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib6","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1093\/nar\/gkz005","article-title":"SMCHD1 is involved in de novo methylation of the DUX4-encoding D4Z4 macrosatellite","volume":"47","author":"Dion","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib7","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/ana.20625","article-title":"Variable hypomethylation of D4Z4 in facioscapulohumeral muscular dystrophy","volume":"58","author":"van Overveld","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2025.101513_bib8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/ng1262","article-title":"Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy","volume":"35","author":"van Overveld","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/01.wnl.0000271391.44352.fe","article-title":"Hypomethylation is restricted to the D4Z4 repeat array in phenotypic FSHD","volume":"69","author":"de Greef","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtm.2025.101513_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/hmg\/ddu486","article-title":"Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2","volume":"24","author":"Lemmers","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib11","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1086\/521986","article-title":"Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy","volume":"81","author":"Lemmers","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib13","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1093\/hmg\/ddu251","article-title":"DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle","volume":"23","author":"Yao","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib14","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib15","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70341","article-title":"iMyoblasts for ex vivo and in vivo investigations of human myogenesis and disease modeling","volume":"11","author":"Guo","year":"2022","journal-title":"eLife"},{"key":"10.1016\/j.omtm.2025.101513_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113011","article-title":"Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy","volume":"320","author":"Mueller","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.omtm.2025.101513_bib17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.22275","article-title":"DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo","volume":"69","author":"Wallace","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtm.2025.101513_bib18","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/mt.2012.68","article-title":"RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy","volume":"20","author":"Wallace","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101513_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192657","article-title":"A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy","volume":"13","author":"Jones","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2025.101513_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13395-020-00227-4","article-title":"Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity","volume":"10","author":"Jones","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtm.2025.101513_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","article-title":"Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD","volume":"8","author":"Wallace","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101513_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123538","article-title":"AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD","volume":"3","author":"Giesige","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2025.101513_bib23","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2025.101513_bib24","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2025.101513_bib25","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101513_bib26","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.ymthe.2020.07.009","article-title":"Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV","volume":"28","author":"Morales","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101513_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/humc.2013.208","article-title":"Feasibility and safety of systemic rAAV9-hNAGLU delivery for treating mucopolysaccharidosis IIIB: toxicology, biodistribution, and immunological assessments in primates","volume":"25","author":"Murrey","year":"2014","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2025.101513_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2025.101513_bib29","doi-asserted-by":"crossref","first-page":"8796","DOI":"10.1093\/nar\/gku531","article-title":"Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice","volume":"42","author":"Prakash","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib30","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/cb501028c","article-title":"siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes","volume":"10","author":"Matsuda","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.omtm.2025.101513_bib31","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbic.201500023","article-title":"Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo","volume":"16","author":"Rajeev","year":"2015","journal-title":"Chembiochem"},{"key":"10.1016\/j.omtm.2025.101513_bib32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.omtn.2016.12.003","article-title":"Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid Therapeutics","volume":"6","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2025.101513_bib33","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1097\/MPH.0000000000002941","article-title":"Givosiran for the Treatment of Pediatric Acute Intermittent Porphyria","volume":"46","author":"Bujold","year":"2024","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.omtm.2025.101513_bib34","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101513_bib35","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101513_bib36","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1093\/hmg\/ddn293","article-title":"Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function","volume":"17","author":"Yin","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib37","doi-asserted-by":"crossref","first-page":"11401","DOI":"10.1093\/nar\/gkac641","article-title":"Enhanced exon skipping and prolonged dystrophin restoration achieved by TfR1-targeted delivery of antisense oligonucleotide using FORCE conjugation in mdx mice","volume":"50","author":"Desjardins","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib38","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1093\/nar\/gkz354","article-title":"Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle","volume":"47","author":"Prakash","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib39","first-page":"6045","article-title":"Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates","volume":"47","author":"Ostergaard","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib40","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib41","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1093\/nar\/gkaa595","article-title":"The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy","volume":"48","author":"Biscans","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib42","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.ymthe.2020.12.023","article-title":"Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles","volume":"29","author":"Biscans","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101513_bib43","article-title":"Potent and durable gene modulation in heart and muscle with chemically defined siRNAs","author":"Fakih","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.omtm.2025.101513_bib44","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2025.101513_bib45","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.celrep.2019.10.025","article-title":"DUX4-Induced Histone Variants H3.X and H3.Y Mark DUX4 Target Genes for Expression","volume":"29","author":"Resnick","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2025.101513_bib46","article-title":"Gene Set Knowledge Discovery with Enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr. Protoc."},{"key":"10.1016\/j.omtm.2025.101513_bib47","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.omtm.2025.101513_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13395-015-0046-6","article-title":"Developmental myosins: expression patterns and functional significance","volume":"5","author":"Schiaffino","year":"2015","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtm.2025.101513_bib50","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/01926233241227942","article-title":"Toxicogenomics Approaches to Address Toxicity and Carcinogenicity in the Liver","volume":"51","author":"Pandiri","year":"2023","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.omtm.2025.101513_bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omtm.2025.101513_bib52","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/978-1-4899-1928-1_17","article-title":"Transport of long-chain fatty acids across the muscular endothelium","volume":"441","author":"Van der Vusse","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omtm.2025.101513_bib53","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/nar\/gkad415","article-title":"Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs)","volume":"51","author":"Malecova","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkaf270","article-title":"Conjugation to a transferrin receptor 1-binding Bicycle peptide enhances ASO and siRNA potency in skeletal and cardiac muscles","volume":"53","author":"Ostergaard","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2025.101513_bib55","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41587-024-02336-7","article-title":"Enhancing siRNA efficacy in vivo with extended nucleic acid backbones","volume":"43","author":"Yamada","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2025.101513_bib56","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ejhg.2011.213","article-title":"A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function","volume":"20","author":"Homma","year":"2012","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib57","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1093\/hmg\/dds284","article-title":"Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis","volume":"21","author":"Jones","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2025.101513_bib58","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nmeth.1226","article-title":"Mapping and quantifying mammalian transcriptomes by RNA-Seq","volume":"5","author":"Mortazavi","year":"2008","journal-title":"Nat. Methods"}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050125001081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T15:20:49Z","timestamp":1762615249000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050125001081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2329050125001081"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101513","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systemically deliverable lipid-conjugated siRNA targeting DUX4 as an facioscapulohumeral muscular dystrophy therapeutic","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2025.101513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"101513"}}